SL
SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
51
Elevance Health
ELV
$70.6B
|
WM
Whit Mayo
| $313.64 | $580 |
85%
upside
| Outperform | 2 years ago |
|
52
Biohaven
BHVN
$1.68B
|
MG
Marc Goodman
| $15.87 | $24 |
51%
upside
| Outperform | 2 years ago |
|
53
Recursion Pharmaceuticals
RXRX
$2.01B
|
MF
Mani Foroohar
| $4.61 | $8 |
74%
upside
| Market Perform | 2 years ago |
|
54
Regenxbio
RGNX
$490M
|
MF
Mani Foroohar
| $9.71 | $14 |
44%
upside
| Market Perform | 2 years ago |
|
55
Rocket Pharmaceuticals
RCKT
$354M
|
MF
Mani Foroohar
| $3.28 | $49 |
1,394%
upside
| Outperform | 2 years ago |
|
56
Intellia Therapeutics
NTLA
$1.29B
|
MF
Mani Foroohar
| $12.06 | $84 |
597%
upside
| Outperform | 2 years ago |
|
57
Beam Therapeutics
BEAM
$2.11B
|
MF
Mani Foroohar
| $20.88 | $77 |
269%
upside
| Outperform | 2 years ago |
|
58
BridgeBio Pharma
BBIO
$10.2B
|
MF
Mani Foroohar
| $53.38 | $19 |
64%
downside
| Outperform | 2 years ago |
|
59
Alnylam Pharmaceuticals
ALNY
$59.2B
|
MF
Mani Foroohar
| $452 | $143 |
68%
downside
| Market Perform | 2 years ago |
|
60
Sarepta Therapeutics
SRPT
$1.96B
|
JS
Joseph Schwartz
| $18.71 | $160 |
755%
upside
| Outperform | 2 years ago |
|
61
Johnson & Johnson
JNJ
$430B
|
DR
David Risinger
| $178.43 | $186 |
4%
upside
| Outperform | 2 years ago |
|
62
Zymeworks
ZYME
$1.14B
|
AB
Andrew Berens
| $15.05 | $10 |
34%
downside
| Market Perform | 2 years ago |
|
63
Evolus
EOLS
$495M
|
MG
Marc Goodman
| $7.66 | $20 |
161%
upside
| Outperform | 2 years ago |
|
64
UnitedHealth
UNH
$286B
|
WM
Whit Mayo
| $315.39 | $625 |
98%
upside
| Outperform | 2 years ago |
|
65
Ascendis Pharma
ASND
$12.5B
|
JS
Joseph Schwartz
| $205.91 | $163 |
21%
downside
| Outperform | 2 years ago |
|
66
Exact Sciences
EXAS
$10.2B
|
PS
Puneet Souda
| $53.81 | $75 |
39%
upside
| Outperform | 2 years ago |
|
67
Mirum Pharmaceuticals
MIRM
$3.82B
|
MF
Mani Foroohar
| $76.06 | $39 |
49%
downside
| Outperform | 2 years ago |
|
68
Viridian Therapeutics
VRDN
$1.53B
|
TS
Thomas Smith
| $18.72 | $45 |
140%
upside
| Outperform | 2 years ago |
|
69
Repligen
RGEN
$7.01B
|
PS
Puneet Souda
| $124.56 | $200 |
61%
upside
| Outperform | 2 years ago |
|
70
AbCellera Biologics
ABCL
$1.26B
|
PS
Puneet Souda
| $4.22 | $18 |
327%
upside
| Outperform | 2 years ago |
|
71
Agilent Technologies
A
$36.5B
|
PS
Puneet Souda
| $128.75 | $170 |
32%
upside
| Outperform | 2 years ago |
|
72
Phreesia
PHR
$1.68B
|
SD
Stephanie Davis
| $28.13 | $39 |
39%
upside
| Outperform | 2 years ago |
|
73
Progyny
PGNY
$1.94B
|
SD
Stephanie Davis
| $22.55 | $34 |
51%
upside
| Market Perform | 2 years ago |
|
74
Cogent Biosciences
COGT
$1.82B
|
AB
Andrew Berens
| $13.05 | $20 |
53%
upside
| Outperform | 2 years ago |
|
75
NewAmsterdam Pharma
NAMS
$3.04B
|
RR
Roanna Ruiz
| $27 | $19 |
30%
downside
| Outperform | 2 years ago |
|